Loading...
Docoh

GSK (GSK)

Filed: 14 Apr 22, 10:59am
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the month of April 2022
 
Commission File Number 001-15170
 
 
GlaxoSmithKline plc
(Translation of registrant's name into English)
 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
 
 
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
 
 
 
GlaxoSmithKline plc (the 'Company')
Transaction notification
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Ms E Walmsley
b)
Position/status
 
Chief Executive Officer
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
 
GlaxoSmithKline plc
b)
LEI
 
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
Nature of the transaction
 
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 April 2022
c)Price(s) and volume(s) 
Price(s)
 
Volume(s) 
 
£17.8437
 
3,336.682 
    
d)
Aggregated information
 
N/A (single transaction)
Aggregated volume
Price
 
 
e)
Date of the transaction
 
2022-04-12
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Mr R Connor
b)Position/status
President, Vaccines and Global Health
 
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
 
GlaxoSmithKline plc
b)
LEI
 
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
Nature of the transaction
 
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 April 2022
c)Price(s) and volume(s) 
Price(s)
 
Volume(s) 
 
£17.8437
 
3,735.169 
    
d)
Aggregated information
 
 
N/A (single transaction)
Aggregated volume
Price
 
 
e)
Date of the transaction
 
2022-04-12
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Ms D Conrad
b)
Position/status
 
Chief People Officer
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
 
GlaxoSmithKline plc
b)
LEI
 
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
Nature of the transaction
 
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 April 2022
c)Price(s) and volume(s) 
Price(s)
 
Volume(s) 
 
£17.8437
 
9.211
 
    
d)
Aggregated information
 
N/A (single transaction)
Aggregated volume
Price
 
 
e)
Date of the transaction
 
2022-04-12
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Mr J Ford
b)
Position/status
 
SVP and Group General Counsel, Legal and Compliance
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
 
GlaxoSmithKline plc
b)
LEI
 
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
Nature of the transaction
 
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 April 2022
c)Price(s) and volume(s) 
Price(s)
 
Volume(s) 
 
£17.8437
 
0.00003
 
    
d)
Aggregated information
 
N/A (single transaction)
Aggregated volume
Price
 
 
e)
Date of the transaction
 
2022-04-12
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Ms S Jackson
b)
Position/status
 
SVP, Global Communications and CEO Office
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
 
GlaxoSmithKline plc
b)
LEI
 
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
Nature of the transaction
 
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 April 2022
c)Price(s) and volume(s) 
Price(s)
 
Volume(s) 
 
£17.8437
 
393.287 
    
d)
Aggregated information
 
N/A (single transaction)
Aggregated volume
Price
 
 
e)
Date of the transaction
 
2022-04-12
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Mr D Jackson
b)
Position/status
 
PCA of Ms S Jackson (SVP, Global Communications and CEO Office)
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
 
GlaxoSmithKline plc
b)
LEI
 
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
Nature of the transaction
 
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 April 2022
c)Price(s) and volume(s) 
Price(s)
 
Volume(s) 
 
£17.8437
 
217.786 
    
d)
Aggregated information
 
 
N/A (single transaction)
Aggregated volume
Price
 
 
e)
Date of the transaction
 
2022-04-12
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Mr L Miels
b)
Position/status
 
Chief Commercial Officer
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
 
GlaxoSmithKline plc
b)LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
Nature of the transaction
 
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 April 2022
c)Price(s) and volume(s) 
Price(s)
 
Volume(s) 
 
£17.8437
 
6,851.731 
    
d)
Aggregated information
 
N/A (single transaction)
 
 
Aggregated volume
Price
 
 
e)
Date of the transaction
 
2022-04-12
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Mr D Redfern
b)
Position/status
 
Chief Strategy Officer
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
 
GlaxoSmithKline plc
b)
LEI
 
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
Nature of the transaction
 
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 April 2022
c)Price(s) and volume(s) 
Price(s)
 
Volume(s) 
 
£17.8437
 
5,469.431 
    
d)
Aggregated information
 
 
N/A (single transaction)
Aggregated volume
Price
 
 
e)
Date of the transaction
 
2022-04-12
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Mr R Simard
b)
Position/status
 
President, Pharmaceuticals Supply Chain
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
 
GlaxoSmithKline plc
b)
LEI
 
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
Nature of the transaction
 
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 April 2022
c)Price(s) and volume(s) 
Price(s)
 
Volume(s) 
 
£17.8437
 
1,304.923 
    
d)
Aggregated information
 
 
N/A (single transaction)
Aggregated volume
Price
 
 
e)
Date of the transaction
 
2022-04-12
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Mr P Thomson
b)
Position/status
 
President, Global Affairs
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
 
GlaxoSmithKline plc
b)
LEI
 
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
Nature of the transaction
 
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 April 2022
c)Price(s) and volume(s) 
Price(s)
 
Volume(s) 
 
£17.8437
 
1,411.217
 
    
d)
Aggregated information
 
 
N/A (single transaction)
Aggregated volume
Price
 
 
e)
Date of the transaction
 
2022-04-12
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Ms K Thomson
b)
Position/status
 
PCA of Mr P Thomson (President, Global Affairs)
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
 
GlaxoSmithKline plc
b)
LEI
 
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
Nature of the transaction
 
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 April 2022
c)Price(s) and volume(s) 
Price(s)
 
Volume(s) 
 
£17.8437
 
156.463
 
    
d)
Aggregated information
 
 
N/A (single transaction)
Aggregated volume
Price
 
 
e)
Date of the transaction
 
2022-04-12
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Ms D Waterhouse
b)
Position/status
 
CEO, ViiV Healthcare
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
 
GlaxoSmithKline plc
b)
LEI
 
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
Nature of the transaction
 
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 April 2022
c)Price(s) and volume(s) 
Price(s)
 
Volume(s) 
 
£17.8437
 
369.424 
    
d)
Aggregated information
 
N/A (single transaction)
Aggregated volume
Price
 
 
e)
Date of the transaction
 
2022-04-12
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
SIGNATURES
 
 
 
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 GlaxoSmithKline plc
 (Registrant)
  
Date: April 14, 2022 
  
 
By:/s/ VICTORIA WHYTE
--------------------------
  
 Victoria Whyte
 Authorised Signatory for and on
 behalf of GlaxoSmithKline plc